Improved sales boost Hyphens Pharma Q1 profit by 97.6%

The Specialty Pharma Principals led the increase in revenue.

Hyphens Pharma International nearly doubled its net profit for the first quarter of 2024 (Q1 2024) to $2.7m backed by robust revenue during the period.

In a bourse filing, the company said revenue was up 44.4% to $48m in Q1 2024 driven by improved sales in all its segments, particularly its Specialty Pharma Principals unit.

“The Specialty Pharma portfolio continues to serve as the primary catalyst for growth in Q1 2024. It has rebounded from supply chain disruptions in H1 2023,” the company noted.

Year-on-year, Hyphens Pharma said this segment has shown significant growth. The introduction of new product portfolios during the latter half of 2023, including offerings from Laboratoires Gilbert S.A.S. and products from the Medical Aesthetics portfolio, further boosts growth prospects for this segment, it added.

“At the same time, we observed similar quarter-on-quarter trending with the Proprietary Brands segment, a reduction in quarter-on-quarter sales could be attributed to the same reason above,” the company said.

Hyphens Pharma noted the increase in revenue was partially offset by the increased distribution and marketing expenses which rose along with the improved sales.

The company’s gross profit also improved 32.8% to $17.4m during the quarter. However, the gross profit margin declined to 36.3% due to continued cost pressure and a higher sales mix of products carrying a lower margin.

ALSO READ: Riverstone logs 54.5% YoY net profit growth in Q124

Recently, Hyphens Pharma announced its partnership with 7-Eleven to offer Ocean Health supplements at selected convenience stores in Singapore, the entrance of Ceradan range into five Middle Eastern markets through exclusive distributorship with Cooper Pharma S.A., and the licence of Wynzora Cream for ASEAN countries from MC2 Therapeutics.

“The above achievements represent our key strategic focus for this segment, which is to further market penetration through widening distribution channels, expanding into new geographical markets, and actively acquiring new products for our ever-growing portfolio,” the company said.

Hyphens Pharma said it also remains focused on its expansion through acquisitions, prioritising those that are aligned with its strategic goals.

Follow the link for more news on

Financial Statements

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.

If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia